

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci crunch.org) on May 24, 2025

HCC2935

RRID:CVCL_1265

Type: Cell Line

Proper Citation

(RRID:CVCL_1265)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1265

Proper Citation: (RRID:CVCL_1265)

Sex: Male

Defining Citation: [PMID:22460905](#), [PMID:22961666](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26361996](#), [PMID:26589293](#), [PMID:26929325](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31803961](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: Deep proteome analysis., Omics: Deep exome analysis., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: HCC2935

Synonyms: HCC-2935, Hamon Cancer Center 2935

Cross References: BTO:BTO_0004083, CLO:CLO_0003654, EFO:EFO_0005375, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:CRL-2869, BioSample:SAMN03471880, BioSample:SAMN10988553, cancercellines:CVCL_1265, Cell_Model_Passport:SIDM01598, ChEMBL-Cells:ChEMBL4523543, ChEMBL-Targets:ChEMBL4523574, Cosmic:903646, Cosmic:1128249, Cosmic:1146933, DepMap:ACH-000150, EGA:EGAS00001000610, GEO:GSM108869, GEO:GSM108870, GEO:GSM253407, GEO:GSM434284, GEO:GSM794397, GEO:GSM844549, GEO:GSM887051, GEO:GSM888121, IARC_TP53:28331, IARC_TP53:30034,

IGRhCellID:HCC2935GEO, LiGeA:CCLE_347, PharmacDB:HCC2935_496_2019, PRIDE:PXD002556, Progenetix:CVCL_1265, PubChem_Cell_line:CVCL_1265, Wikidata:Q54881680

ID: CVCL_1265

Record Creation Time: 20250131T200323+0000

Record Last Update: 20250131T201524+0000

Ratings and Alerts

No rating or validation information has been found for HCC2935.

No alerts have been found for HCC2935.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Guerrero Zuniga A, et al. (2024) Sustained ERK signaling promotes G2 cell cycle exit and primes cells for whole-genome duplication. *Developmental cell*, 59(13), 1724.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Ishibashi K, et al. (2024) Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR. *Developmental cell*, 59(5), 579.

Marrocco I, et al. (2023) L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. *Cell reports. Medicine*, 4(8), 101142.

Martin MJ, et al. (2022) Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells. *Cancer research communications*, 2(10), 1312.

Inoue Y, et al. (2021) Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer. *eLife*, 10.